Perspective Therapeutics’ (CATX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Perspective Therapeutics (NYSE:CATX) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

Other research analysts also recently issued reports about the company. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Saturday, July 12th. B. Riley reiterated a “buy” rating and set a $12.00 price objective (up previously from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Finally, Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.56.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $3.64 on Friday. The stock has a 50 day moving average of $3.53 and a 200 day moving average of $3.09. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $13.56.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its holdings in shares of Perspective Therapeutics by 227.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 242,610 shares of the company’s stock valued at $835,000 after acquiring an additional 168,448 shares during the period. Bank of America Corp DE boosted its position in Perspective Therapeutics by 8.5% during the second quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock valued at $1,127,000 after purchasing an additional 25,697 shares in the last quarter. Federated Hermes Inc. grew its stake in Perspective Therapeutics by 44.4% in the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after purchasing an additional 60,019 shares during the last quarter. Walleye Capital LLC grew its stake in Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after purchasing an additional 148,013 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Perspective Therapeutics by 118.4% in the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after purchasing an additional 405,612 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.